STAT+: AI drug firm Pathos raises $237 million, pushing valuation to $3 billion
Reported by STAT News · all stories from statnews.com
Editorial digest
Biotechnology enterprise Pathos completed a $237 million funding round, driving its market valuation to $3 billion. The capital increase underscores ongoing financial momentum behind computational platforms designed to accelerate pharmaceutical development.
Digests are written in our own words from the publisher's headline — we never reproduce article text. Read the original for the full reporting.
Read the full story at STAT News →More like this
Other stories our editors tagged with the same themes.
- Trusted health newsroom11/4/2026
STAT+: The biotech startups skipping AI for drug discovery
Some emerging biotechnology firms are choosing to bypass artificial intelligence tools when developing new pharmaceuticals.
- Trusted health newsroom11/10/2026
STAT+: Oura to acquire Counsel Health for $625 million, placing a big bet on AI care
Oura plans to purchase Counsel Health in a $625 million deal focused on artificial intelligence healthcare services.
- Trusted health newsroom10/28/2026
STAT+: Why every health care AI company must face Epic
A report examines why developers of medical artificial intelligence must inevitably contend with electronic health record giant Epic.
- Trusted health newsroom10/21/2026
STAT+: What’s the deal with Isomorphic Labs?
A new report examines the current standing and operations of drug discovery venture Isomorphic Labs.
- Trusted health newsroom10/28/2026
STAT+: As Epic’s dominance grows, its iron grip is choking innovation in health technology
Epic Systems' expanding market influence is reportedly stifling technological innovation across the healthcare sector.
- Trusted health newsroom10/14/2026
STAT+: The startup chasing ‘general biological intelligence’
A new company is pursuing advanced biological AI capabilities.